Date published: 2026-9-10

1-800-457-3801

SCBT Portrait Logo
Seach Input

CHCHD6 CRISPR/Cas9 KO Plasmid (m): sc-425817

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: mouse
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • CHCHD6 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
  • gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the CHCHD6 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
  • The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    CHCHD6 CRISPR/Cas9 KO Plasmid (m)

    sc-425817
    20 µg
    $397.00

    Overview

    Chchd6 encodes CHCHD6, a coiled-coil-helix-coiled-coil-helix domain protein enriched at mitochondria where it supports inner mitochondrial membrane organization and cristae architecture. CHCHD6 has been linked to mitochondrial contact site and cristae organizing system (MICOS)-related processes that coordinate membrane curvature, respiratory chain assembly, and mitochondrial dynamics. Through these roles, CHCHD6 influences oxidative phosphorylation efficiency, reactive oxygen species balance, and mitochondrial stress signaling that can impact cell survival and differentiation programs. Dysregulation of mitochondrial ultrastructure and bioenergetic homeostasis is relevant to models of neurodegeneration, cardiometabolic dysfunction, and other disorders where mitochondrial integrity is a key experimental endpoint.

    CHCHD6 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Chchd6 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Chchd6 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

    The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Chchd6 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish CHCHD6 protein expression.

    This CRISPR knockout system enables efficient generation of Chchd6-deficient cell models for investigation of CHCHD6 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

    Key Features

    • sgRNAs targeting Chchd6 exon(s) critical for CHCHD6 function
    • Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
    • GFP reporter for identification of transfected cells
    • Pool of plasmids targeting multiple Chchd6 genomic sites to improve knockout efficiency
    • Compatible with delivery by transfection

    Design Variants

    CRISPRs +/- HDRs

    • gRNAs encoded by CHCHD6 CRISPR/Cas9 KO Plasmid (m) and CHCHD6 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Chchd6 locus. One or both targeting designs may be available. See Related Products for availability.
    • HDR donor constructs encoded by CHCHD6 HDR Plasmid (m) and CHCHD6 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Chchd6 homology arms to support homology-directed repair at defined Chchd6 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.